A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn's disease patients in sustained steroid-free remission on combination therapy
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Infliximab (Primary) ; Azathioprine; Mercaptopurine; Methotrexate
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SPARE
- 03 Oct 2017 Planned End Date changed from 12 Aug 2018 to 1 Dec 2021.
- 03 Oct 2017 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
- 10 Jun 2017 Biomarkers information updated